The continuation of its administration AstraZeneca vaccine without changes announced the National Vaccination Committee in Austria after the decision of the European Medicines Agency, as its use had not been suspended in the country.
Based on the EMA assessment, it is recommended to continue the vaccination program unchanged, as the vaccine is not associated with an increased overall risk of blood clots (thromboembolic events), as reminded by AMPE.
“The benefits of the vaccine in combating its still widespread threat COVID-19 still outweigh the risk of side effects. There is no indication of a problem with any batch of vaccine or with a specific place of production., underlined in the announcement.
According to the Austrian National Vaccination Committee, the AstraZeneca vaccine is not associated with an increased overall risk of blood clots.
In women under 55 there is an indication of a very low risk (less than 1: 100,000) of a rare form of coagulation disorder with blood clots after COVID-19 vaccination and this should be noted in the pre-vaccination briefing.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
